ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Allarity Therapeutics, Inc. for alleged violations of the Securities Exchange Act, specifically related to misleading statements about the company's regulatory submissions and the risks associated with them [1][2]. Group 1: Lawsuit Details - The lawsuit pertains to investors who purchased Allarity's securities between May 17, 2022, and July 19, 2024, and encourages them to contact the Schall Law Firm before November 12, 2024 [1]. - The complaint alleges that Allarity and its executives made false and misleading statements regarding the Dovitinib NDA and Dovitinib-DRP PMA, which increased the company's exposure to regulatory scrutiny [2]. - The company is accused of downplaying the likelihood of enforcement actions after an investigation was announced, leading to materially misleading public statements throughout the class period [2]. Group 2: Investor Participation - Investors are invited to join the class action to recover their losses, with the Schall Law Firm specializing in securities class action lawsuits and shareholder rights litigation [3].